ammographic breast density reflects the relative amounts of fat versus fibroglandular tissues in the breast (1) and is an established risk factor for breast cancer (2). Women with the highest level of breast density have four to six times the risk for breast cancer compared with women with the lowest levels of density (3), and high density is associated with larger and more aggressive tumors (4). Moreover, breast density can affect the sensitivity of mammography because of masking of tumors (5). As of December 2018, over 70% of states in the United States passed legislation mandating that women be notified of their breast density. In some states, women with high breast density are advised to both discuss the implication of their density with their health care provider and consider supplemental screening methods (6). The most commonly used breast density assessment is the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) (1). The BI-RADS system includes four categories of breast density (a, almost entirely fatty; b, scattered areas of fibroglandular density; c, hetereogeneously dense; and, d, extremely dense). According to most state notification laws, women assigned the latter two breast density categories are considered to have dense breasts whereas the first two density categories are considered nondense. In many states, having dense breast parenchyma prompts supplemental screening, most often with breast US. Studies show a strong relationship of high BI-RADS breast density categories to cancer risk (2), risk of masking (5), and high-risk benign breast disease (7).